Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcome.
diffuse large B-cell lymphoma
late relapse
retrospective study
rituximab
survival
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
09
01
2019
accepted:
21
05
2019
pubmed:
7
8
2019
medline:
9
7
2020
entrez:
7
8
2019
Statut:
ppublish
Résumé
Diffuse large B-cell lymphoma (DLBCL) constitutes 25-35% of all non-Hodgkin lymphomas in Western countries. Approximately two thirds of the patients can be cured with standard immuno-chemotherapy. Most relapses occur within 1-2 years from diagnosis, however, the occurrence of relapses after 5 years or more has been described. We aimed at defining the incidence and clinical features of late relapses. Data of 1113 DLBCL patients were analysed. Among the 196 patients relapsing after a first complete remission, 36 (18% of relapses and 3% of all DLBCLs) experienced a recurrence more than 5 years from diagnosis. Late relapsing patients, in comparison with those relapsing earlier, showed a more favourable risk profile at presentation: normal lactate dehydrogenase levels (P = 0·002), early Ann Arbor stage (P = 0·006) and low International Prognostic Index (P = 0·003). The risk of late relapse was lowered by the introduction of rituximab as part of the front-line treatment (P < 0·001). Cause-specific survival (CSS) from the time of relapse was significantly better for late relapsing patients compared to those relapsing early: 5-year CSS rates were 53% and 31%, respectively (P = 0·033). A trend toward a better overall survival was also observed, with 5-year rates after relapse of 47% and 25%, respectively (P = 0·054).
Substances chimiques
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
478-487Informations de copyright
© 2019 British Society for Haematology and John Wiley & Sons Ltd.
Références
Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A., Boldrick, J.C., Sabet, H., Tran, T., Yu, X., Powell, J.I., Yang, L., Marti, G.E., Moore, T., Hudson, J. Jr, Lu, L., Lewis, D.B., Tibshirani, R., Sherlock, G., Chan, W.C., Greiner, T.C., Weisenburger, D.D., Armitage, J.O., Warnke, R., Levy, R., Wilson, W., Grever, M.R., Byrd, J.C., Botstein, D., Brown, P.O. & Staudt, L.M. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403, 503-511.
Altman, D.G., De Stavola, B.L., Love, S.B. & Stepniewska, K.A. (1995) Review of survival analyses published in cancer journals. British Journal of Cancer, 72, 511-518.
Anderson, T., Bender, R.A., Fisher, R.I., DeVita, V.T., Chabner, B.A., Berard, C.W., Norton, L. & Young, R.C. (1977) Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup. Cancer Treatment Reports, 61, 1057-1066.
Armitage, J.O., Gascoyne, R.D., Lunning, M.A. & Cavalli, F. (2017) Non-Hodgkin lymphoma. Lancet, 390, 298-310.
Broseus, J., Chen, G., Hergalant, S., Ramstein, G., Mounier, N., Gueant, J.L., Feugier, P., Gisselbrecht, C., Thieblemont, C. & Houlgatte, R. (2016) Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses. Oncotarget, 7, 83987-84002.
Cabanillas, F., Velasquez, W., Hagemeister, F., McLaughlin, P. & Redman, J. (1992) Clinical, biologic, and histologic features of late relapses in diffuse large cell lymphoma. Blood, 79, 1024-1028.
Chapuy, B., Stewart, C., Dunford, A.J., Kim, J., Kamburov, A., Redd, R.A., Lawrence, M.S., Roemer, M.G.M., Li, A.J., Ziepert, M., Staiger, A.M., Wala, J.A., Ducar, M.D., Leshchiner, I., Rheinbay, E., Taylor-Weiner, A., Coughlin, C.A., Hess, J.M., Pedamallu, C.S., Livitz, D., Rosebrock, D., Rosenberg, M., Tracy, A.A., Horn, H., van Hummelen, P., Feldman, A.L., Link, B.K., Novak, A.J., Cerhan, J.R., Habermann, T.M., Siebert, R., Rosenwald, A., Thorner, A.R., Meyerson, M.L., Golub, T.R., Beroukhim, R., Wulf, G.G., Ott, G., Rodig, S.J., Monti, S., Neuberg, D.S., Loeffler, M., Pfreundschuh, M., Trumper, L., Getz, G. & Shipp, M.A. (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nature Medicine, 24, 679-690.
Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
Chiappella, A., Martelli, M., Angelucci, E., Brusamolino, E., Evangelista, A., Carella, A.M., Stelitano, C., Rossi, G., Balzarotti, M., Merli, F., Gaidano, G., Pavone, V., Rigacci, L., Zaja, F., D'Arco, A., Cascavilla, N., Russo, E., Castellino, A., Gotti, M., Congiu, A.G., Cabras, M.G., Tucci, A., Agostinelli, C., Ciccone, G., Pileri, S.A. & Vitolo, U. (2017) Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. The Lancet Oncology, 18, 1076-1088.
Coiffier, B., Thieblemont, C., Van Den Neste, E., Lepeu, G., Plantier, I., Castaigne, S., Lefort, S., Marit, G., Macro, M., Sebban, C., Belhadj, K., Bordessoule, D., Ferme, C. & Tilly, H. (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood, 116, 2040-2045.
Cox, D.R. (1972) Regression models and life tables. Journal of the Royal Statistical Society: Series B (Methodological), 34, 187-220.
Cunningham, D., Hawkes, E.A., Jack, A., Qian, W., Smith, P., Mouncey, P., Pocock, C., Ardeshna, K.M., Radford, J.A., McMillan, A., Davies, J., Turner, D., Kruger, A., Johnson, P., Gambell, J. & Linch, D. (2013) Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet, 381, 1817-1826.
Davies, A.J., Caddy, J., Maishman, T., Barrans, S., Mamot, C., Care, M., Pocock, C., Stanton, L., Hamid, D., Pugh, K., McMillan, A., Fields, P., Kruger, A., Jack, A. & Johnson, P.W.M. (2015) A Prospective randomised trial of targeted therapy for diffuse large B-cell lymphoma (DLBCL) based upon real-time gene expression profiling: the Remodl-B study of the UK NCRI and SAKK lymphoma groups (ISRCTN51837425). Blood, 126, 812-812.
Delarue, R., Tilly, H., Mounier, N., Petrella, T., Salles, G., Thieblemont, C., Bologna, S., Ghesquieres, H., Hacini, M., Fruchart, C., Ysebaert, L., Ferme, C., Casasnovas, O., Van Hoof, A., Thyss, A., Delmer, A., Fitoussi, O., Molina, T.J., Haioun, C. & Bosly, A. (2013) Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. The Lancet Oncology, 14, 525-533.
Fisher, R.I., Gaynor, E.R., Dahlberg, S., Oken, M.M., Grogan, T.M., Mize, E.M., Glick, J.H., Coltman, C.A. Jr & Miller, T.P. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine, 328, 1002-1006.
Gine, E. & Sehn, L.H. (2016) Diffuse large B-cell lymphoma: should limited-stage patients be treated differently? Hematology/Oncology Clinics of North America, 30, 1179-1194.
Gisselbrecht, C., Glass, B., Mounier, N., Singh Gill, D., Linch, D.C., Trneny, M., Bosly, A., Ketterer, N., Shpilberg, O., Hagberg, H., Ma, D., Briere, J., Moskowitz, C.H. & Schmitz, N. (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. Journal of Clinical Oncology, 28, 4184-4190.
Head, D.R., Avakian, J., Kjeldsberg, C.R. & Cerezo, L. (1988) Relapse of intermediate or high-grade (unfavorable) non-Hodgkin's lymphoma as a low-grade (favorable) Non-Hodgkin's lymphoma. Report of four cases. American Journal of Clinical Pathology, 89, 106-108.
Jakobsen, L.H., Bogsted, M., Brown, P.N., Arboe, B., Jorgensen, J., Larsen, T.S., Juul, M.B., Schurmann, L., Hojberg, L., Bergmann, O.J., Lassen, T., Josefsson, P.L., Jensen, P., Johnsen, H.E. & El-Galaly, T.C. (2017) Minimal loss of lifetime for patients with diffuse large B-cell lymphoma in remission and event free 24 months after treatment: a Danish population-based study. Journal of Clinical Oncology, 35, 778-784.
Jiang, Y., Redmond, D., Nie, K., Eng, K.W., Clozel, T., Martin, P., Tan, L.H., Melnick, A.M., Tam, W. & Elemento, O. (2014) Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas. Genome Biology, 15, 432.
de Jong, D., Glas, A.M., Boerrigter, L., Hermus, M.-C., Dalesio, O., Willemse, E., Nederlof, P.M. & Kersten, M.J. (2003) Very late relapse in diffuse large B-cell lymphoma represents clonally related disease and is marked by germinal center cell features. Blood, 102, 324-327.
Juskevicius, D., Lorber, T., Gsponer, J., Perrina, V., Ruiz, C., Stenner-Liewen, F., Dirnhofer, S. & Tzankov, A. (2016) Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis. Leukemia, 30, 2385-2395.
Juskevicius, D., Dirnhofer, S. & Tzankov, A. (2017) Genetic background and evolution of relapses in aggressive B-cell lymphomas. Haematologica, 102, 1139-1149.
Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of American Statistical Association, 53, 457-481.
Ko, A.H. & Yuen, A.R. (2002) Clinical outcomes associated with very late relapses in diffuse large cell lymphoma. Leukemia & Lymphoma, 43, 1789-1793.
Larouche, J.-F., Berger, F., Chassagne-Clément, C., Ffrench, M., Callet-Bauchu, E., Sebban, C., Ghesquières, H., Broussais-Guillaumot, F., Salles, G. & Coiffier, B. (2010) Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome. Journal of Clinical Oncology, 28, 2094-2100.
Lee, A.Y., Connors, J.M., Klimo, P., O'Reilly, S.E. & Gascoyne, R.D. (1997) Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B. Journal of Clinical Oncology, 15, 1745-1753.
Lenz, G., Wright, G., Dave, S.S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., Vose, J., Bast, M., Fu, K., Weisenburger, D.D., Greiner, T.C., Armitage, J.O., Kyle, A., May, L., Gascoyne, R.D., Connors, J.M., Troen, G., Holte, H., Kvaloy, S., Dierickx, D., Verhoef, G., Delabie, J., Smeland, E.B., Jares, P., Martinez, A., Lopez-Guillermo, A., Montserrat, E., Campo, E., Braziel, R.M., Miller, T.P., Rimsza, L.M., Cook, J.R., Pohlman, B., Sweetenham, J., Tubbs, R.R., Fisher, R.I., Hartmann, E., Rosenwald, A., Ott, G., Muller-Hermelink, H.K., Wrench, D., Lister, T.A., Jaffe, E.S., Wilson, W.H., Chan, W.C. & Staudt, L.M. (2008) Stromal gene signatures in large-B-cell lymphomas. New England Journal of Medicine, 359, 2313-2323.
Lossos, A., Ashhab, Y., Sverdlin, E., Amir, G., Ben-Yehuda, D. & Siegal, T. (2004) Late-delayed cerebral involvement in systemic non-Hodgkin lymphoma. Cancer, 101, 1843-1849.
Martinez, R.L.M.C. & Naranjo, J.D. (2010) A pretest for choosing between logrank and wilcoxon tests in the two-sample problem. METRON, 68, 111-125.
Maurer, M.J., Habermann, T.M., Shi, Q., Schmitz, N., Cunningham, D., Pfreundschuh, M., Seymour, J.F., Jaeger, U., Haioun, C., Tilly, H., Ghesquieres, H., Merli, F., Ziepert, M., Herbrecht, R., Flament, J., Fu, T., Flowers, C.R. & Coiffier, B. (2018) Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Annals of Oncology, 29, 1822-1827.
McKelvey, E.M., Gottlieb, J.A., Wilson, H.E., Haut, A., Talley, R.W., Stephens, R., Lane, M., Gamble, J.F., Jones, S.E., Grozea, P.N., Gutterman, J., Coltman, C. & Moon, T.E. (1976) Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer, 38, 1484-1493.
Modvig, L., Vase, M. & d'Amore, F. (2017) Clinical and treatment-related features determining the risk of late relapse in patients with diffuse large B-cell lymphoma. British Journal of Haematology, 179, 75-82.
Morikawa, K., Tsuji, T., Yamasaki, H., Toyozumi, Y., Arima, N., Ohshima, K. & Tsuda, H. (2013) Central nervous system lymphoma newly developed 12 years after remission of an ocular adnexal lymphoma. Acta Haematologica, 130, 247-250.
Nishiuchi, R., Yoshino, T., Teramoto, N., Sakuma, I., Hayashi, K., Nakamura, S., Seino, Y. & Akagi, T. (1996) Clonal analysis by polymerase chain reaction of B-cell lymphoma with late relapse: a report of five cases. Cancer, 77, 757-762.
Nowakowski, G.S., Chiappella, A., Witzig, T.E., Spina, M., Gascoyne, R.D., Zhang, L., Flament, J., Repici, J. & Vitolo, U. (2016) ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Future Oncology, 12, 1553-1563.
Reddy, A., Zhang, J., Davis, N.S., Moffitt, A.B., Love, C.L., Waldrop, A., Leppa, S., Pasanen, A., Meriranta, L., Karjalainen-Lindsberg, M.L., Norgaard, P., Pedersen, M., Gang, A.O., Hogdall, E., Heavican, T.B., Lone, W., Iqbal, J., Qin, Q., Li, G., Kim, S.Y., Healy, J., Richards, K.L., Fedoriw, Y., Bernal-Mizrachi, L., Koff, J.L., Staton, A.D., Flowers, C.R., Paltiel, O., Goldschmidt, N., Calaminici, M., Clear, A., Gribben, J., Nguyen, E., Czader, M.B., Ondrejka, S.L., Collie, A., Hsi, E.D., Tse, E., Au-Yeung, R.K.H., Kwong, Y.L., Srivastava, G., Choi, W.W.L., Evens, A.M., Pilichowska, M., Sengar, M., Reddy, N., Li, S., Chadburn, A., Gordon, L.I., Jaffe, E.S., Levy, S., Rempel, R., Tzeng, T., Happ, L.E., Dave, T., Rajagopalan, D., Datta, J., Dunson, D.B. & Dave, S.S. (2017) Genetic and functional drivers of diffuse large B cell lymphoma. Cell, 171, 481-494.e415.
Rizzo, D., Viailly, P.J., Mareschal, S., Bohers, E., Picquenot, J.M., Penther, D., Dubois, S., Marchand, V., Bertrand, P., Maingonnat, C., Etancelin, P., Feuillard, J., Bastard, C., Tilly, H., Jardin, F. & Ruminy, P. (2017) Oncogenic events rather than antigen selection pressure may be the main driving forces for relapse in diffuse large B-cell lymphomas. American Journal of Hematology, 92, 68-76.
Robins, H.I., Aubuchon, J.P., Hafez, G.R., Bozdech, M.J., Steeves, R. & Davis, T.E. (1984) Late recurrences of histiocytic lymphoma after treatment. Cancer, 53, 2663-2667.
Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, R.I., Gascoyne, R.D., Muller-Hermelink, H.K., Smeland, E.B., Giltnane, J.M., Hurt, E.M., Zhao, H., Averett, L., Yang, L., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D., Powell, J., Duffey, P.L., Longo, D.L., Greiner, T.C., Weisenburger, D.D., Sanger, W.G., Dave, B.J., Lynch, J.C., Vose, J., Armitage, J.O., Montserrat, E., Lopez-Guillermo, A., Grogan, T.M., Miller, T.P., LeBlanc, M., Ott, G., Kvaloy, S., Delabie, J., Holte, H., Krajci, P., Stokke, T. & Staudt, L.M. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 1937-1947.
Sanz, L., López-Guillermo, A., Martínez, C., Bosch, F., Esteve, J., Cobo, F., Montoto, S., Perales, M., Bladé, J., Cervantes, F., Nomdedeu, B., Campo, E. & Montserrat, E. (1998) Risk of relapse and clinico-pathological features in 103 patients with diffuse large-cell lymphoma in complete response after first-line treatment. European Journal of Haematology, 61, 59-64.
Schmitz, R., Wright, G.W., Huang, D.W., Johnson, C.A., Phelan, J.D., Wang, J.Q., Roulland, S., Kasbekar, M., Young, R.M., Shaffer, A.L., Hodson, D.J., Xiao, W., Yu, X., Yang, Y., Zhao, H., Xu, W., Liu, X., Zhou, B., Du, W., Chan, W.C., Jaffe, E.S., Gascoyne, R.D., Connors, J.M., Campo, E., Lopez-Guillermo, A., Rosenwald, A., Ott, G., Delabie, J., Rimsza, L.M., Tay Kuang Wei, K., Zelenetz, A.D., Leonard, J.P., Bartlett, N.L., Tran, B., Shetty, J., Zhao, Y., Soppet, D.R., Pittaluga, S., Wilson, W.H. & Staudt, L.M. (2018) Genetics and pathogenesis of diffuse large B-cell lymphoma. New England Journal of Medicine, 378, 1396-1407.
Sehn, L.H., Donaldson, J., Chhanabhai, M., Fitzgerald, C., Gill, K., Klasa, R., MacPherson, N., O'Reilly, S., Spinelli, J.J., Sutherland, J., Wilson, K.S., Gascoyne, R.D. & Connors, J.M. (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. Journal of Clinical Oncology, 23, 5027-5033.
Shipp, M.A., Ross, K.N., Tamayo, P., Weng, A.P., Kutok, J.L., Aguiar, R.C., Gaasenbeek, M., Angelo, M., Reich, M., Pinkus, G.S., Ray, T.S., Koval, M.A., Last, K.W., Norton, A., Lister, T.A., Mesirov, J., Neuberg, D.S., Lander, E.S., Aster, J.C. & Golub, T.R. (2002) Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature Medicine, 8, 68-74.
Stiff, P.J., Unger, J.M., Cook, J.R., Constine, L.S., Couban, S., Stewart, D.A., Shea, T.C., Porcu, P., Winter, J.N., Kahl, B.S., Miller, T.P., Tubbs, R.R., Marcellus, D., Friedberg, J.W., Barton, K.P., Mills, G.M., LeBlanc, M., Rimsza, L.M., Forman, S.J. & Fisher, R.I. (2013) Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. New England Journal of Medicine, 369, 1681-1690.
Strussmann, T., Fritsch, K., Baumgarten, A., Fietz, T., Engelhardt, M., Mertelsmann, R., Ihorst, G., Duyster, J., Finke, J. & Marks, R. (2017) Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation. British Journal of Haematology, 178, 927-935.
Swerdlow, S.H., Campo, E., Pileri, S.A., Harris, N.L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G.A., Zelenetz, A.D. & Jaffe, E.S. (2016) The 2016 revision to the World Health Organization classification of lymphoid neoplasm. Blood, 127, 2375-2390.
Thieblemont, C., Briere, J., Mounier, N., Voelker, H.U., Cuccuini, W., Hirchaud, E., Rosenwald, A., Jack, A., Sundstrom, C., Cogliatti, S., Trougouboff, P., Boudova, L., Ysebaert, L., Soulier, J., Chevalier, C., Bron, D., Schmitz, N., Gaulard, P., Houlgatte, R. & Gisselbrecht, C. (2011) The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. Journal of Clinical Oncology, 29, 4079-4087.
Tilly, H., Gomes da Silva, M., Vitolo, U., Jack, A., Meignan, M., Lopez-Guillermo, A., Walewski, J., André, M., Johnson, P.W., Pfreundschuh, M. & Ladetto, M. (2015) Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 26, v116-v125.
Vose, J.M., Weisenburger, D.D., Loberiza, F.R., Arevalo, A., Bast, M., Armitage, J., Bierman, P.J., Bociek, R.G. & Armitage, J.O. (2010) Late relapse in patients with diffuse large B-cell lymphoma. British Journal of Haematology, 151, 354-358.
Wang, Y., Farooq, U., Link, B.K., Hefazi, M., Allmer, C., Witzig, T.E., Habermann, T.M., Ansell, S.M., Cerhan, J.R. & Nowakowski, G.S. (2018) Relapses after achieving EFS24 in patients with diffuse large B-cell lymphoma in the rituximab era. Blood, 132, 454.
Wilson, W.H., Young, R.M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., Lih, C.J., Williams, P.M., Shaffer, A.L., Gerecitano, J., de Vos, S., Goy, A., Kenkre, V.P., Barr, P.M., Blum, K.A., Shustov, A., Advani, R., Fowler, N.H., Vose, J.M., Elstrom, R.L., Habermann, T.M., Barrientos, J.C., McGreivy, J., Fardis, M., Chang, B.Y., Clow, F., Munneke, B., Moussa, D., Beaupre, D.M. & Staudt, L.M. (2015) Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nature Medicine, 21, 922-926.